A number of medtech companies announced that they received millions of dollars in loans through the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Cutera (NSDQ:CUTR), Senseonics (NYSE:SENS), Viveve Medical (NSDQ:VIVE) and Encision (ECIA:ECIA) received approximately $15 million combined through the program administered by the U.S. Small Business Administration amid the COVID-19 pandemic. […]
Senseonics
Senseonics enters $20m credit facility
Senseonics (NYSE:SENS) announced today that it entered into a new senior secured term loan agreement worth $15 million with potential for an additional $5 million. The agreement is with certain funds managed by existing stakeholder Highbridge Capital Management. Senseonics is slated to draw down $15 million from the new first lien secured term loan with a […]
Senseonics, Companion Medical to integrate sensor glucose and insulin data
Senseonics (NYSE:SENS) will integrate its Eversense continuous glucose monitoring (CGM) system’s real-time glucose data with Companion Medical‘s InPen smart insulin delivery system. The agreement between Senseonics and Companion, announced today, is slated to bring the technologies together to allow real-time glucose data to be continuously incorporated into the InPen insulin system. This is designed to allow for more relevant […]
7 medtech advances to improve diabetes treatment
Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
Senseonics launches Eversense CGM System with non-adjunctive claim
Senseonics (NYSE:SENS) this week said it launched its Eversense continuous glucose monitoring system with its mobile app that can dose based on the system’s readings. The Eversense System is a long-term, implantable CGM sensor that features a transmitter that sends discreet vibrations to alert users of low and high glucose levels. The system with the CGM […]
Senseonics lists $200 million offering
Senseonics (NYSE:SENS) posted a $200 million offering of common stock, preferred stock, debt securities and/or warrants, including an agreement for Jefferies to handle $50 million. The total offering includes the company’s common stock, which was trading at $1.03 per share in midday trading today. Senseonics — which makes glucose monitoring products — said the securities in […]
Senseonics touts Humana reimbursement nod for Eversense CGM
Senseonics (NYSE:SENS) said yesterday that Humana is now providing coverage for its Eversense continuous glucose monitoring system and insertion procedure. Humana is the fifth-largest health insurer in the U.S. with 17 million patients in 50 states, Washington, D.C. and Puerto Rico, according to a news release. Its coverage policy with Senseonics makes patients with Type 1 […]
Senseonics touts Eversense reimbursement win
Senseonics (NYSE:SENS) said this week that Health Care Service Corporation – Blue Cross Blue Shield is providing coverage for the Eversense continuous glucose monitoring system, effective as of yesterday. HCSC – Blue Cross Blue Shield is the fourth-largest health insurer in the U.S. and serves more than 16 million members, according to a news release. Last […]
Senseonics touts BCBS reimbursement wins
Senseonics (NYSE:SENS) said today that Blue Cross Blue Shield of Massachusetts and Idaho now provide coverage for the implantable Eversense continuous glucose monitor. The company’s Eversense device includes a fluorescence-based sensor, a mobile app and a transmitter. Senseonics’ touts its system as being the first with a long-term, implantable CGM sensor, as well as the first […]
Senseonics touts long-term safety data on home-use Eversense
Senseonics (NYSE:SENS) yesterday touted real-world data it said demonstrated the safety and lack of adverse events with its Eversense continuous glucose monitoring system for people with diabetes. Eversense is a long-term, implantable GCM sensor with a transmitter that sends discreet vibrations to alert users of low or high glucose. The device can be removed, recharged and […]
Senseonics touts real-world CGM data
Senseonics (NYSE:SENS) announced yesterday that real-world data from its Eversense continuous glucose monitoring system reflected strong performance and safety. The data, published in Diabetes Technology and Therapeutics, included the first 205 U.S. patients to use Germantown, Md.-based Senseonics’ Eversense system over a 90-day wear period. Zero device or procedure-related adverse events were reported with the […]